Pharmacokinetics of the insulin-sensitizing agent troglitazone in cats

American Journal of Veterinary Research

Volumn 61, Issue 7, 2000, Pages 775-778

  Michels, Gina M ^a,b   Boudinot, F Douglas ^a   Ferguson, Duncan C ^a   Hoenig, Margarethe ^a  

^a UNIVERSITY OF GEORGIA   (United States)

^b ZOETIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TROGLITAZONE;

ANIMAL EXPERIMENT; ARTICLE; CAT; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG URINE LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; NONHUMAN;

ANIMALIA; FELIS CATUS;

EID: 0033947727     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.2000.61.775     Document Type: Article

References (23)

1. Loi C, Alvey CW, Randinitis EJ, et al. Meta-analysis of steady-state pharmacokinetics of troglitazone and its metabolites. J Clin Pharmacol 1997;37:1038-1047.
2. Lehman JM, Moore LB, Smith-Oliver TA, et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPAR γ). J Biol Chem 1995;270: 12953-12956.
3. Auboeuf D, Rieusset J, Fajas L, et al. Tissue distribution and quantification of the expression of messenger-RNAs of peroxisome proliferator-activated receptors and liver-X-receptor-alpha in humans - no alteration in adipose-tissue of obese and NIDDM patients. Diabetes 1997;46:1319-1327.
4. Fajas L, Auboeuf D, Raspe E, et al. Organization, promoter analysis and expression of the human PPAR γ gene. J Biol Chem 1997;272:18779-18789.
5. Schoonjans K, Staels B, Auwerx J. Role of the peroxisome proliferator activated receptor (PPAR) in mediating effects of fibrates and fatty acids on gene expression. J Lipid Res 1996;37:907-925.
6. Schoonjans K, Staels B, Auwerx J. The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta 1996;1302:93-109.
7. Schoonjans K, Martin G, Staels B, et al. Peroxisome proliferator activated receptors, orphans with ligands and functions. Curr Opin Lipidol 1997;8:159-166.
8. Martin G, Schoonjans K, Staels B, et al. PPAR gamma activators improve glucose homeostasis by stimulating fatty acid uptake in the adipocytes. Atherosclerosis 1998;137(suppl):75-80.
9. Roden M, Price TB, Perseghin G, et al. Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest 1996;97:2859-2865.
10. Dagogo-Jack S, Santiago J. Pathophysiology of type 2 diabetes and modes of action of therapeutic interventions. Arch Intern Med 1997;157:1802-1817.
11. Sparano N, Seaton T. Troglitazone in type II diabetes mellitus. Pharmacotherapy 1998;18:539-548.
12. Fujiwara T, Yoshioka S, Yoshioka T, et al. Characterization of new oral antidiabetic agent CS-045 studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 1988;37:1549-1558.
13. Watkins P, Whitcomb R. Hepatic dysfunction associated with troglitazone. N Engl J Med 1998;338:916-917.
14. Imura H. A novel antidiabetic drug, troglitazone - reason for hope and concern. New Engl J Med 1998;338:908-909.
15. Izumi T, Enomoto S, Hosiyama K, et al. Prediction of the human pharmacokinetics of troglitazone, a new and extensively metabolized antidiabetic agent, after oral administration, with an animal scale-up approach. J Pharmacol Exp Ther 1996;277:1630-1641.
16. Rocci ML, Jusko WJ. LAGRAN program for area and moments in pharmacokinetic analysis. Comput Prog Biomed 1983;16;203-216.
17. Lam FC, Hung CT, Perrier DG. Estimation of variance for harmonic mean half-lives. J Pharm Sci 1985;74:229-231.
18. Altman PI, Dittmer DS. Respiration and circulation. Biology data book. 2nd ed. Washington, DC: Federation of American Societies for Experimental Biology, 1974;1571-1744.
19. Spector WS. Handbook of biological data. Philadelphia: WB Saunders Co, 1956;138-186.
20. Kawai K, Kawasaki-Yokui Y, Odaka T, et al. Disposition and metabolism of the new oral antidiabetic drug troglitazone in rats, mice and dogs. Arzneimittelforschung 1997;47:356-368.
21. Wilcke JR. Principles of drug therapy. In: Sherding RG, ed. The cat: diseases and clinical management. New York: Churchill Livingstone Inc, 1994;23-34.
22. Chew DJ, de Morais HS. Parenteral fluid therapy. In: Sherding RG, ed. The cat: diseases and clinical management. 2nd ed. New York: Churchill Livingstone Inc, 1994;39-89.
23. Spencer CM, Markham A. Troglitazone. Drugs 1997;54: 89-101.